Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Adding Japanese Patent, Aidi Pharma Accelerates Overseas Layout of New Anti-AIDS Drug
Recently, Jiangsu Aidi Pharmaceutical Group officially received a patent certificate from the Japan Patent Office. The company’s core anti-HIV drug and new integrase inhibitor ACC017 have added new momentum to their global expansion. As of now, Phase III clinical trials for ACC017 have officially commenced, and its combination formulation ADC118 has also been approved for clinical trials. The development process is progressing steadily. (People’s Financial News)